Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
All content for The Lancet in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
Lene Seidler on umbilical cord management at preterm birth
The Lancet in conversation with
14 minutes
1 year ago
Lene Seidler on umbilical cord management at preterm birth
Lene Seidler joins Callam Davidson of The Lancet to discuss umbilical cord clamping strategies at preterm birth following the publication of two systemic review and meta-analyses with individual participant data.Read the full articles:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02468-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancethttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02469-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancetContinue...
The Lancet in conversation with
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...
